Physician profile
Robert S Quinn
NPI 1700959871
$6,014.72
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,308 · 2020: $2,261 · 2021: $428 · 2024: $18.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $532.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $499.85 | 2019-2021 | |
| Amgen INC. | $426.24 | 2019-2021 | |
| Amarin Pharma, INC. | $402.04 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $371.78 | 2019-2020 | |
| Novo Nordisk INC | $368.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $349.26 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $316.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $299.64 | 2019-2020 | |
| Lilly USA, LLC | $275.47 | 2019-2021 | |
| Allergan, INC. | $241.24 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.88 | 2019-2021 | |
| Astellas Pharma US INC | $207.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $191.17 | 2019-2021 | |
| Esperion Therapeutics, INC. | $186.31 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $165.46 | 2019-2020 | |
| Boston Scientific Corporation | $148.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.28 | 2019-2020 | |
| Abbvie INC. | $107.49 | 2019-2021 | |
| Glaxosmithkline, LLC. | $96.25 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $63.03 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $61.56 | 2019 | |
| Ibsa Pharma INC. | $58.42 | 2019-2020 | |
| Eisai INC. | $44.34 | 2020 | |
| Arbor Pharmaceuticals, INC. | $39.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.24 | 2019 | |
| Ethicon US, LLC | $31.20 | 2019-2020 | |
| Genentech USA, INC. | $30.18 | 2019-2020 | |
| Abbott Laboratories | $20.64 | 2019 | |
| Puma Biotechnology, INC. | $18.42 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2020 | |
| Nestle Healthcare Nutrition INC. | $17.78 | 2021 | |
| Tanabe Pharma America, INC. | $13.97 | 2020 | |
| Gilead Sciences, INC. | $11.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.